EGON-ZEHNDER
28.5.2019 07:02:25 CEST | Business Wire | Press release
Egon Zehnder, the world’s leadership consulting firm, has formalized an agreement to purchase a minority stake in Zurich, Switzerland-based Sinequanon (SQN), a firm that uses AI and advanced analytics to improve workplace culture and performance. SQN is the first to have cracked the code linking culture to performance consistently over time and in every client engagement.
The investment in SQN signals Egon Zehnder’s intent to build on its 55 years of experience shaping leadership and culture through SQN’s unique combination of advanced technology and a human approach to leadership. The companies will work together to disseminate SQN’s Living Analytics™ platform and Flow Operating System™.
SQN’s flowOS™ uses a data-driven and AI-enabled process to identify an organization’s optimal culture and then drives the behavioral change needed by individuals, teams and business units. In its work with clients, flowOS™ has consistently delivered significant improvements in people energy and productivity.
“We hear consistently from clients that culture change is one of the most challenging aspects of leadership. In SQN we have found an innovative partner to deliver integrated services to our clients by marrying both human leadership insights and pioneering technology,” said Jill Ader, Chairwoman, Egon Zehnder. “We strongly believe the best consulting services we can offer our clients combine technology and humanity,” she added.
The partnership is founded on the shared belief that culture change is critical to helping organizations adapt to and thrive in today’s complex world. It combines Egon Zehnder’s expertise advising and unlocking the potential of senior leaders with SQN’s ability to assess and accelerate the power of the full organization through cultural change.
“It has always frustrated me that large organizations trap massive amounts of human energy. In fact, our data shows that less than 10% of employees operate at their full potential. Now as organizations are feeling the brutal effect of disruption, an extraordinary win-win opportunity between employees and businesses is emerging. My life’s mission is to find a business-minded method to enable this – and that is flowOS™,” said Per Lagerstrom, Chief Executive Officer, SQN. “Egon Zehnder and SQN share a core mission to unlock human potential. I believe we can make magic together, and am excited to be partnering with them,” he added.
“We believe the world needs more great leaders. In fact, recent research we conducted with 402 CEOs revealed they find culture change one of the most challenging aspects of the role,” noted Gabriel Andrade, Partner, Egon Zehnder and Board member, SQN. “With SQN, the intelligence of the end-to-end operating system and guided support we can provide clients can change human resources and performance management for the foreseeable future.”
SQN brings new capabilities to an already powerful set of partnerships. Egon Zehnder’s strategic alliance with Mobius Executive Leadership, the London and Cambridge, MA-based leadership development firm, delivers customized executive development programs at the CEO and executive levels that enable breakthroughs often described by participants as “life changing,” which in turn can serve as a multiplier to the impact of SQN. In addition, Egon Zehnder has partnered with Paradox Strategies, the consulting firm co-founded by Harvard University Professor Linda Hill, to develop the Innovation Quotient (IQ), a proprietary culture diagnostic based on Hill’s research that helps clients better understand the degree to which their cultures enable – or inhibit – their ability to innovate.
Notes to Editors
Sinequanon (SQN) is a privately held PeopleTech start-up founded in 2015. While we work globally and across industries, our home is in Switzerland with operations in South Africa and the Czech Republic.
SQN has a passionate team of 60, unified by a fundamental belief in our ability as humans to radically change and grow and a hunger to marry the soft skills with the hard. Our people work across behavioral, neural and data science, technology and client services.
At SQN, we believe that human capital management and change consulting are ripe for disruption. We have combined data, science and sound business principles into a ground breaking approach that taps into the well of human energy, so often trapped in large businesses, delivering material improvements to both the employee experience and the company’s bottom line.
We offer a suite of culture change products and services under the Living Analytics™ and flowOS™ brands, coupled with a disruptive tech enabled client delivery model.
About Egon Zehnder
Egon Zehnder is the world’s leadership consulting firm, sharing one goal: to transform people, organizations and the world through great leadership.
We know what great leaders can do and are passionate about delivering the best leadership solutions for our clients.
As One Firm, our more than 480 Consultants in 68 offices and 40 countries bring our individual strengths to form one powerful collaborative team.
We partner closely with public and private corporations, family-owned enterprises, and non-profit and government agencies to provide Board advisory services, CEO search and succession, executive search, executive assessment, leadership development and organizational transformation.
We offer a range of integrated services to support our leadership consulting work: Our strategic alliance with Mobius Executive Leadership, the London and Cambridge, MA based leadership development firm, delivers customized executive development programs at the CEO and executive levels that enable breakthroughs often described by participants as “life changing.” In addition, we have partnered with Paradox Strategies, the consulting firm co-founded by Harvard University Professor Linda Hill, to develop the Innovation Quotient (IQ), a proprietary culture diagnostic based on Hill’s research that helps clients better understand the degree to which their cultures enable – or inhibit – their ability to innovate.
We share a commitment and pride in doing work that contributes to successful careers, stronger companies and a better world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190527005228/en/
Contact:
Global media Hilary Crnkovich Global Head of Marketing and Communications P: +1 312-260-8978
Stacy Drumtra US Head of Marketing and Communications P: +1 312-260-8974
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
